Clinical Trial

Community-acquired Pneumonia Due to Chlamydia Pneumoniae

Study acronym: CHLAMPAC
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This international retrospective Franco-Swiss study focuses on community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae. The working hypothesis is that the prevalence of C. pneumoniae pneumonia is overestimated by the medical community. The primary objective is to determine the true prevalence of C. pneumoniae infections among patients with pneumonia who underwent simplex or multiplex PCR testing. Secondary objectives include; 1. Outpatient management 2. Hospitalization in a medical ward 3. Admission to the intensive care unit 4. In-hospital mortality 5. Radiological presentation of patients with community-acquired pneumonia (CAP) caused by Chlamydia pneumoniae 6. Prevalence of viral or bacterial co-infections associated with C. pneumoniae CAP
Trial Details
NCT Number NCT07679789
Lead Sponsor Centre Hospitalier de Saint-Denis
Conditions Community-Acquired Pneumonia
Enrollment 200 participants
Start Date 2026-06
Primary Completion 2026-09 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-01